SCHEMBL2648339

SCHEMBL2648339

O=C(O)CCSc1cnc(NC(=O)N(C2CCCCCC2)[C@H]2CC[C@H](c3ccccc3)CC2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 12/20 0.43
CDK2 P24941 12/20 0.43
CCNE2 O96020 7/20 0.43
CDK5 Q00535 5/20 0.40
CDK5R1 Q15078 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
OGA O60502 1/20 0.38
HTT P42858 1/20 0.38
GRM4 Q14833 1/20 0.37
CDK4 P11802 4/20 0.36
CCND1 P24385 4/20 0.36
CCNB2 O95067 2/20 0.36
CDK1 P06493 2/20 0.36
CCNB1 P14635 2/20 0.36
CCNB3 Q8WWL7 2/20 0.36
DGAT1 O75907 1/20 0.35
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648343 1.00 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL2649607 1.00 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL2649611 1.00 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL2648454 0.91 CCNE1 (0.41) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL999706 0.91 CCNE1 (0.41) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL2648451 0.91 CCNE1 (0.41) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL2650468 0.91 CCNE1 (0.41) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL1002462 0.91 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL1000207 0.91 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1
SCHEMBL998883 0.91 CCNE1 (0.43) CCNE1CDK2CCNE2CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 CCNE1 2454/4885CDK2 253/4885CCNE2 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.